These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19675198)

  • 1. Correlation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patients.
    Araki S; Matsuno H; Haneda M; Koya D; Kanno Y; Itho J; Kishi A; Isshiki K; Sugimoto T; Maegawa H; Kashiwagi A; Uzu T
    Diabetes Care; 2009 Nov; 32(11):2062-7. PubMed ID: 19675198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro.
    Racanelli AL; Gibbs SK; Zondlo SC; Seiffert DA; Friedman SM; Feuerstein GZ
    Thromb Res; 2003 May; 110(2-3):99-105. PubMed ID: 12893024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa.
    Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA
    Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased platelet activation in subjects chronically exposed to cadmium: A pilot study.
    Nontarach A; Srihirun S; Chaturapanich G; Unchern S; Swaddiwudhipong W; Pattanapanyasat K; Chamchoi A; Vivithanaporn P; Visoottiviseth P; Sibmooh N
    Platelets; 2016; 27(2):136-42. PubMed ID: 26023812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of platelet aggregability in Japanese type 2 diabetic patients with and without microalbuminuria.
    Baba T; Kodama T; Yasuda TK; Ishizaki T
    Diabet Med; 1993; 10(7):643-6. PubMed ID: 8403826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and shedding of platelet glycoprotein IIb/IIIa under non-physiological shear stress.
    Chen Z; Mondal NK; Ding J; Koenig SC; Slaughter MS; Griffith BP; Wu ZJ
    Mol Cell Biochem; 2015 Nov; 409(1-2):93-101. PubMed ID: 26160282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
    Schneider DJ; Hardison RM; Lopes N; Sobel BE; Brooks MM;
    Diabetes Care; 2009 May; 32(5):944-9. PubMed ID: 19228864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
    Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
    Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
    Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
    Michelson AD; Furman MI; Goldschmidt-Clermont P; Mascelli MA; Hendrix C; Coleman L; Hamlington J; Barnard MR; Kickler T; Christie DJ; Kundu S; Bray PF
    Circulation; 2000 Mar; 101(9):1013-8. PubMed ID: 10704169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T; Koppensteiner R; Panzer S
    PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
    Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
    Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels].
    Khaspekova SG; Ziuriaev IT; Iakushkin VV; Naĭmushin IaA; Sirotkina OV; Zaĭtseva NO; Ruda MIa; Mazurov AV
    Biomed Khim; 2014; 60(1):94-108. PubMed ID: 24749250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications.
    Holmes MB; Sobel BE; Howard DB; Schneider DJ
    Thromb Res; 1999 Jul; 95(2):75-82. PubMed ID: 10418796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.